MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
Arbutus Biopharma Corporation Operating Cycle 2011-2026 | ABUS
Annual Operating Cycle Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 | 124 | 31.5 | 10.5 | 36.7 | 69.3 | 73.1 | 112 | 29.7 | 170 | 20.3 | 61.7 | 8.71 | 89 | 30.6 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 170 | 8.71 | 61.1 |
Quarterly Operating Cycle Arbutus Biopharma Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 166 | 9.38 | 92.9 | - | 115 | 103 | 117 | - | 46.9 | 51.8 | 27.4 | - | 14.1 | 4.21 | 8.02 | - | 40.5 | 50.2 | 55.6 | - | 78.6 | 79.1 | 77 | 67.9 | 35.9 | 168 | 177 | 53.5 | 53.5 | 74.9 | 35.6 | 14.5 | 5.32 | 35.3 | 131 | -128 | 32.2 | 80.6 | 96.9 | 7.25 | 22.6 | 26.7 | 28.4 | 39.9 | 39.8 | 95.9 | 20.8 | 14.2 | 3.6 | 3.75 | 25.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 177 | -128 | 52.2 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Amgen
AMGN
|
282 | $ 349.77 | 0.57 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
237 | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 14.6 | 0.76 % | $ 6.06 B |  Irlanda |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Benitec Biopharma
BNTC
|
141 | $ 11.19 | 1.91 % | $ 461 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |